IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20

Detalhes bibliográficos
Autor(a) principal: REZENDE,MÁRCIA UCHÔA DE
Data de Publicação: 2020
Outros Autores: GURGEL,HENRIQUE MELO CAMPOS, OCAMPOS,GUILHERME PEREIRA, CAMPOS,GUSTAVO CONSTANTINO DE, FRUCCHI,RENATO, PAILO,ALEXANDRE FELÍCIO, PASQUALIN,THIAGO, VICENTE,JOSÉ RICARDO NEGREIROS, CAMARGO,OLAVO PIRES DE
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Acta Ortopédica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522020000600280
Resumo: ABSTRACT Objective: To verify whether the use of Hylan G-F20 improves saline lavage and triamcinolone injection results in the treatment of hip osteoarthritis (HOA). Methods: 82 patients with HOA categorized as grades II and III severity, according to Kellgren and Lawrence criteria, were randomized into the groups: lavage and triamcinolone (G0); lavage, triamcinolone, and 2 mL of hylan G-F20 (G1); lavage, triamcinolone, and 4mL of hylan G-F20 (G2); lavage, triamcinolone, and 6mL of hylan G-F20 (G3). The VAS, range of motion (ROM), WOMAC, and Lequesne questionnaires were administered at baseline, one, three, six, and twelve months post-injection. Results: All groups showed clinically relevant improvements (> 20%) between baseline and first month post-injection, maintaining subjective results throughout the study period (p < 0.001). We found no differences between groups in any subjective evaluations (p > 0.05, for all). G2 and G3 obtained improved flexion results up to a year (p = 0.028). Hylan groups presented an improved external rotation since the first postoperative month and maintained the results up to a year (G1, p = 0.041; G2, p = 0.007), whereas G0 showed no improvement (p = 0.336). Conclusion: Hip lavage and triamcinolone injection, with or without the use of hylan, improves pain, function, and quality of life up to a year in HOA. Hylan may improve ROM up to one year. Level of Evidence IB, Randomized clinical trial.
id SBOT-1_e7e64605bdac128f60fcd50a43401fb6
oai_identifier_str oai:scielo:S1413-78522020000600280
network_acronym_str SBOT-1
network_name_str Acta Ortopédica Brasileira (Online)
repository_id_str
spelling IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20Hyaluronic AcidViscosupplementationTriamcinoloneOsteoarthritis, HipRandomized Controlled TrialMinimal Clinically Important DifferenceABSTRACT Objective: To verify whether the use of Hylan G-F20 improves saline lavage and triamcinolone injection results in the treatment of hip osteoarthritis (HOA). Methods: 82 patients with HOA categorized as grades II and III severity, according to Kellgren and Lawrence criteria, were randomized into the groups: lavage and triamcinolone (G0); lavage, triamcinolone, and 2 mL of hylan G-F20 (G1); lavage, triamcinolone, and 4mL of hylan G-F20 (G2); lavage, triamcinolone, and 6mL of hylan G-F20 (G3). The VAS, range of motion (ROM), WOMAC, and Lequesne questionnaires were administered at baseline, one, three, six, and twelve months post-injection. Results: All groups showed clinically relevant improvements (> 20%) between baseline and first month post-injection, maintaining subjective results throughout the study period (p < 0.001). We found no differences between groups in any subjective evaluations (p > 0.05, for all). G2 and G3 obtained improved flexion results up to a year (p = 0.028). Hylan groups presented an improved external rotation since the first postoperative month and maintained the results up to a year (G1, p = 0.041; G2, p = 0.007), whereas G0 showed no improvement (p = 0.336). Conclusion: Hip lavage and triamcinolone injection, with or without the use of hylan, improves pain, function, and quality of life up to a year in HOA. Hylan may improve ROM up to one year. Level of Evidence IB, Randomized clinical trial.ATHA EDITORA2020-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522020000600280Acta Ortopédica Brasileira v.28 n.6 2020reponame:Acta Ortopédica Brasileira (Online)instname:Sociedade Brasileira de Ortopedia e Traumatologia (SBOT)instacron:SBOT10.1590/1413-785220202806240075info:eu-repo/semantics/openAccessREZENDE,MÁRCIA UCHÔA DEGURGEL,HENRIQUE MELO CAMPOSOCAMPOS,GUILHERME PEREIRACAMPOS,GUSTAVO CONSTANTINO DEFRUCCHI,RENATOPAILO,ALEXANDRE FELÍCIOPASQUALIN,THIAGOVICENTE,JOSÉ RICARDO NEGREIROSCAMARGO,OLAVO PIRES DEeng2020-12-01T00:00:00Zoai:scielo:S1413-78522020000600280Revistahttp://www.actaortopedica.com.br/https://old.scielo.br/oai/scielo-oai.php1atha@uol.com.br||actaortopedicabrasileira@uol.com.br1809-44061413-7852opendoar:2020-12-01T00:00Acta Ortopédica Brasileira (Online) - Sociedade Brasileira de Ortopedia e Traumatologia (SBOT)false
dc.title.none.fl_str_mv IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
title IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
spellingShingle IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
REZENDE,MÁRCIA UCHÔA DE
Hyaluronic Acid
Viscosupplementation
Triamcinolone
Osteoarthritis, Hip
Randomized Controlled Trial
Minimal Clinically Important Difference
title_short IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
title_full IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
title_fullStr IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
title_full_unstemmed IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
title_sort IMPROVEMENTS IN HIP OSTEOARTHRITIS WITH LAVAGE, TRIAMCINOLONE AND HYLAN G-F20
author REZENDE,MÁRCIA UCHÔA DE
author_facet REZENDE,MÁRCIA UCHÔA DE
GURGEL,HENRIQUE MELO CAMPOS
OCAMPOS,GUILHERME PEREIRA
CAMPOS,GUSTAVO CONSTANTINO DE
FRUCCHI,RENATO
PAILO,ALEXANDRE FELÍCIO
PASQUALIN,THIAGO
VICENTE,JOSÉ RICARDO NEGREIROS
CAMARGO,OLAVO PIRES DE
author_role author
author2 GURGEL,HENRIQUE MELO CAMPOS
OCAMPOS,GUILHERME PEREIRA
CAMPOS,GUSTAVO CONSTANTINO DE
FRUCCHI,RENATO
PAILO,ALEXANDRE FELÍCIO
PASQUALIN,THIAGO
VICENTE,JOSÉ RICARDO NEGREIROS
CAMARGO,OLAVO PIRES DE
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv REZENDE,MÁRCIA UCHÔA DE
GURGEL,HENRIQUE MELO CAMPOS
OCAMPOS,GUILHERME PEREIRA
CAMPOS,GUSTAVO CONSTANTINO DE
FRUCCHI,RENATO
PAILO,ALEXANDRE FELÍCIO
PASQUALIN,THIAGO
VICENTE,JOSÉ RICARDO NEGREIROS
CAMARGO,OLAVO PIRES DE
dc.subject.por.fl_str_mv Hyaluronic Acid
Viscosupplementation
Triamcinolone
Osteoarthritis, Hip
Randomized Controlled Trial
Minimal Clinically Important Difference
topic Hyaluronic Acid
Viscosupplementation
Triamcinolone
Osteoarthritis, Hip
Randomized Controlled Trial
Minimal Clinically Important Difference
description ABSTRACT Objective: To verify whether the use of Hylan G-F20 improves saline lavage and triamcinolone injection results in the treatment of hip osteoarthritis (HOA). Methods: 82 patients with HOA categorized as grades II and III severity, according to Kellgren and Lawrence criteria, were randomized into the groups: lavage and triamcinolone (G0); lavage, triamcinolone, and 2 mL of hylan G-F20 (G1); lavage, triamcinolone, and 4mL of hylan G-F20 (G2); lavage, triamcinolone, and 6mL of hylan G-F20 (G3). The VAS, range of motion (ROM), WOMAC, and Lequesne questionnaires were administered at baseline, one, three, six, and twelve months post-injection. Results: All groups showed clinically relevant improvements (> 20%) between baseline and first month post-injection, maintaining subjective results throughout the study period (p < 0.001). We found no differences between groups in any subjective evaluations (p > 0.05, for all). G2 and G3 obtained improved flexion results up to a year (p = 0.028). Hylan groups presented an improved external rotation since the first postoperative month and maintained the results up to a year (G1, p = 0.041; G2, p = 0.007), whereas G0 showed no improvement (p = 0.336). Conclusion: Hip lavage and triamcinolone injection, with or without the use of hylan, improves pain, function, and quality of life up to a year in HOA. Hylan may improve ROM up to one year. Level of Evidence IB, Randomized clinical trial.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522020000600280
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522020000600280
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1413-785220202806240075
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv ATHA EDITORA
publisher.none.fl_str_mv ATHA EDITORA
dc.source.none.fl_str_mv Acta Ortopédica Brasileira v.28 n.6 2020
reponame:Acta Ortopédica Brasileira (Online)
instname:Sociedade Brasileira de Ortopedia e Traumatologia (SBOT)
instacron:SBOT
instname_str Sociedade Brasileira de Ortopedia e Traumatologia (SBOT)
instacron_str SBOT
institution SBOT
reponame_str Acta Ortopédica Brasileira (Online)
collection Acta Ortopédica Brasileira (Online)
repository.name.fl_str_mv Acta Ortopédica Brasileira (Online) - Sociedade Brasileira de Ortopedia e Traumatologia (SBOT)
repository.mail.fl_str_mv 1atha@uol.com.br||actaortopedicabrasileira@uol.com.br
_version_ 1752122276852006912